Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
66.69
+0.10 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...
Via
Benzinga
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
December 19, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
Via
Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
December 19, 2023
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.
Via
InvestorPlace
(GILD) - Analyzing Gilead Sciences's Short Interest
December 18, 2023
Via
Benzinga
A Look Into Gilead Sciences Inc's Price Over Earnings
December 07, 2023
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
December 06, 2023
Via
Benzinga
Looking Into Gilead Sciences's Recent Short Interest
November 22, 2023
Via
Benzinga
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
December 16, 2023
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.
Via
The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying.
December 12, 2023
Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
December 12, 2023
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
December 11, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
November 21, 2023
Via
Benzinga
Is NASDAQ:GILD suited for dividend investing?
November 20, 2023
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD).
Via
Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
November 15, 2023
Via
Benzinga
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions
December 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion...
Via
Benzinga
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
Via
InvestorPlace
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Via
The Motley Fool
A Closer Look at Gilead Sciences's Options Market Dynamics
November 09, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
November 09, 2023
Via
Benzinga
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
There's no time like the present to buy these stocks.
Via
The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
November 21, 2023
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied
Via
Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...
Via
Benzinga
Exposures
Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
November 17, 2023
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying.
Via
Chartmill
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
November 15, 2023
The companies will work together on treatments for multiple myeloma and lymphomas.
Via
Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
November 07, 2023
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.